175278-29-2

Basic information

• Product Name: METHYL 2-METHYL-5-FLUOROBENZOATE
• Synonyms: RARECHEM AL BF 0505;METHYL 2-METHYL-5-FLUOROBENZOATE;METHYL 5-FLUORO-2-METHYLBENZOATE;5-fluoro-2-methylbenzoate
• CAS NO: 175278-29-2
• Molecular Formula: C₉H₉FO₂
• Molecular Weight: 168.16
• Mol File: 175278-29-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 90-92°C 15mm
• Flash Point: 79.884 °C
• Appearance: /
• Density: 1.138 g/cm³
• Vapor Pressure: 0.178mmHg at 25°C
• Refractive Index: 1.491
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: METHYL 2-METHYL-5-FLUOROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-METHYL-5-FLUOROBENZOATE(175278-29-2)
• EPA Substance Registry System: METHYL 2-METHYL-5-FLUOROBENZOATE(175278-29-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 175278-29-2(Hazardous Substances Data)

Usage

Description

METHYL 2-METHYL-5-FLUOROBENZOATE is a chemical compound with the molecular formula C9H9FO2, typically appearing as a clear liquid or white solid. It is an organic ester that is susceptible to hydrolysis in the presence of acids or bases and is also flammable, requiring careful handling to prevent exposure to open flames or high heat. It is commonly used in the field of organic synthesis and as a pharmaceutical intermediate.

Uses

Used in Organic Synthesis:
METHYL 2-METHYL-5-FLUOROBENZOATE is used as a chemical intermediate for the synthesis of various organic compounds. Its unique structure and reactivity make it a valuable building block in the creation of complex organic molecules.
Used in Pharmaceutical Industry:
METHYL 2-METHYL-5-FLUOROBENZOATE is used as a pharmaceutical intermediate for the development of new drugs. Its specific functional groups and properties allow it to be incorporated into the molecular structures of potential therapeutic agents, contributing to their pharmacological properties and efficacy.
Despite its frequent use in industry, there is limited information available on the potential toxicity or environmental impact of METHYL 2-METHYL-5-FLUOROBENZOATE. Further research is needed to fully understand its effects and ensure safe and responsible use in various applications.

InChI:InChI=1/C9H9FO2/c1-6-3-4-7(10)5-8(6)9(11)12-2/h3-5H,1-2H3

Upstream product

• 33184-16-6 5-fluoro-2-methylbenzoic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 

Downstream Products

• 884504-23-8 3-(5-fluoro-2-methylphenyl)-3-oxopropanenitrile 
• 1187318-53-1 methyl 3-bromo-5-fluoro-2-methylbenzoate 
• 606080-44-8 methyl-2-(aminomethyl)-5-fluorobenzoate hydrochloride 
• 1082040-43-4 6-fluoro-1H-indole-4-carboxylic acid methyl ester 
• 697739-03-0 5-fluoro-2-methyl-3-nitrobenzoic acid methyl ester 
• 138786-63-7 2-(5-{3-[(E)-2-(7-Chloro-quinolin-2-yl)-vinyl]-phenyl}-tetrazol-2-ylmethyl)-5-fluoro-benzoic acid 
• 606080-42-6 5-(1,1-dioxido-1,2-thiazinan-2-yl)-N-{4-fluoro-2-[(methylamino)carbonyl]benzyl}-8-hydroxy-1,6-naphthyridine-7-carboxamide 
• 569354-60-5 N-methyl 2-aminomethyl-5-fluorobenzenecarboxamide HCl salt 
• 569354-58-1 C₁₉H₂₆FNO₆ 
• 569354-59-2 N-methyl 2-t-butyloxycarbonylaminomethyl-5-fluorobenzenecarboxamide 
• 138786-65-9 methyl 2-(bromomethyl)-5-fluorobenzoate 

Relevant articles and documents

Copper-promoted direct amidation of isoindolinone scaffolds by sodium persulfate

Isoindolinones are ubiquitous structural motifs in natural products and pharmaceuticals. Establishing an efficient method for structural modification of isoindolinones could significantly facilitate new drug development. Herein, we describe copper-promoted direct amidation of isoindolinone scaffolds mediated by sodium persulfate. The method exhibits mild reaction conditions and high site-selectivity, and enables the structural modification of the drug indobufen ester with various amides with yields of 49 to 98%. It is also gram-scalable. Additionally, the reaction mechanism appears to involve a radical and a carbocationic pathway.

Preparation method of ovarian cancer resistance medicine Rucaparib key intermediate

The invention discloses a preparation method of an ovarian cancer resistance medicine Rucaparib key intermediate, and relates to preparation of medical intermediates. A compound 1 takes methyl alcoholand cyclohexane as solvents, toluenesulfonic acid serve

Biaryl substituted hydantoin compounds as TACE inhibitors

We disclose further optimization of hydantoin TNF-α convertase enzyme (TACE) inhibitors. SAR with respect to the non-prime region of TACE active site was explored. A series of biaryl substituted hydantoin compounds was shown to have sub-nanomolar Ki